Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-19FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for ibandronate sodium from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Efficacy and Safety of MW031 in PMO Subjects [Phase 3]
Phase 3 trial update on MW031 for osteoporosis in postmenopausal patients completed, reporting efficacy and safety results.
-
FDA approval · 2023-10-02FDA Approved: ANGELIQ — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Angeliq (drospi renone and estradiol) from Bayer, updating labeling for postmenopausal indicatio…
-
FDA approval · 2023-09-06FDA Approved: ESTRADIOL — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' original application for a generic Estradiol product.
-
CLINICAL_TRIALS trial_result · 2023-08-02Clinical Trial Update: Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration [Phase 4]
Phase 4 clinical trial update examining bone modeling effects of combined anabolic/antiresorptive therapy in postmenopausal osteoporosis; re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-06-23FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for ibandronate sodium submitted by Apotex Corp as part of an ANDA, representing a regulatory update…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Comparative Antiresorptive Efficacy Discontinuation of Denosumab [Phase 4]
A Phase 4 trial update on discontinuation of denosumab evaluating antiresorptive efficacy in osteoporosis conditions may influence managemen…
-
FDA approval · 2023-06-06FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM from Aurobindo Pharma Limited, enabling the approved generic formulation to b…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss [Phase 4]
Phase 4 trial update on Pearlium®/Effecti-Cal®, a calcium, vitamin D and minerals formulation for prevention of postmenopausal bone loss.
-
CLINICAL_TRIALS trial_result · 2023-03-08Clinical Trial Update: Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis [Phase 3]
Phase 3 trial assessing biosimilar denosumab (GP2411) in postmenopausal osteoporosis completed with results posted.
-
FDA approval · 2023-02-15FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for ibandronate sodium submitted by Bionpharma Inc. under ANDA078998.
-
CLINICAL_TRIALS trial_result · 2023-02-15Clinical Trial Update: Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis [Phase 3]
Phase 3 trial update on abaloparatide-solid microstructured transdermal system for postmenopausal osteoporosis shows efficacy and safety res…
-
FDA approval · 2023-01-31FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for alendronate sodium from Amneal Pharmaceuticals of New York LLC for use as a generic product …
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis [Phase 4]
Phase 4 trial evaluating microRNA levels under denosumab and teriparatide therapy in postmenopausal osteoporosis (completed).
-
FDA approval · 2022-12-19FDA Approved: TYMLOS — Supplemental Application (Radius Health, Inc.)
FDA approved a supplemental application for TYMLOS (abaloparatide) submitted by Radius Health, Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-09Clinical Trial Update: Efficacy and Safety of Minodronate in Patients With Low Back Pain [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of minodronate in patients with postmenopausal osteoporosis and low back pain.
-
FDA approval · 2022-12-06FDA Approved: DUAVEE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for Duavee (conjugated estrogens/bazedoxifene) submitted by Wyeth Pharmaceuticals (Pfizer) to update…
-
FDA approval · 2022-10-11FDA Approved: RALOXIFENE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for raloxifene hydrochloride from Amneal Pharmaceuticals LLC, authorizing a regulatory change under …
-
CLINICAL_TRIALS trial_result · 2022-07-18Clinical Trial Update: Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis [Phase 2]
Phase 2 clinical trial update evaluating efficacy and safety of JMT103 in postmenopausal osteoporosis.
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women [Phase 4]
Phase 4 trial assessing effectiveness and safety of EuBone capsules for bone health in postmenopausal women with osteoporosis.
-
CLINICAL_TRIALS trial_result · 2022-02-03Clinical Trial Update: FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051) [Phase 3]
A long-term extension of the FIT fracture intervention trial (Phase 3) for osteoporosis in postmenopausal individuals has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-02Clinical Trial Update: Study of Investigational Drug in Osteoporosis (MK-0217-908) [Phase 3]
Phase 3 trial update for investigational drug MK-0217-908 in postmenopausal osteoporosis has completed.
-
FDA approval · 2021-11-15FDA Approved: CLIMARA PRO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for CLIMARA PRO, the estradiol/levonorgestrel transdermal patch from Bayer HealthCare Pharmaceutical…
-
FDA approval · 2021-11-10FDA Approved: CALCITONIN SALMON — Original Application (Par Health USA, LLC)
The FDA approved Par Health USA's generic Calcitonin Salmon under ANDA 209358.
-
FDA approval · 2021-10-07FDA Approved: CLIMARA PRO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Climara Pro (estradiol and levonorgestrel) submitted by Bayer, potentially updating labeling…